SAMHD1 and cancer: Several suggestions have been made to target SAMHD1 in order to improve nucleoside-based anti-cancer therapies, including treatment with Vpx to degrade SAMHD1 [102] and treatment with RNR inhibitors to induce dNTP-pool imbalances and impede SAMHD1 allosteric activation [214].